For the Quarter Ending March 2025
North America
The North American 10-Methoxy Iminostilbene market exhibited a volatile price trajectory in Q1 2025, shaped by shifting demand dynamics, trade policy uncertainties, and evolving supply chain conditions. January began on a bullish note, with prices rising on the back of strong pharmaceutical demand, constrained supply, and logistical bottlenecks at key ports. Congestion at the Port of Los Angeles, labor shortages, and rising freight costs disrupted distribution and amplified inventory challenges, supporting elevated price levels.
However, February marked a sharp downturn in pricing. Weak downstream demand, particularly in the pharmaceutical sector, combined with elevated inventories due to pre-holiday stockpiling and front-loaded imports from China, led to market saturation. Declining freight rates and stable production costs in exporting regions added competitive pressure on domestic suppliers, prompting price reductions amid reduced purchasing activity.
In March, the bearish trend continued as oversupply conditions persisted. The introduction of new tariffs and escalating trade tensions between the U.S. and China disrupted procurement strategies and weakened buyer sentiment. A decline in the U.S. Manufacturing PMI and a drop in the Consumer Price Index signaled cooling industrial activity and demand. Overall, Q1 2025 in North America reflected a transition from early-quarter firmness to sustained price erosion driven by oversupply and trade-related caution.
Asia Pacific
The Chinese 10-Methoxy Iminostilbene market experienced mixed pricing dynamics throughout Q1 2025, shaped by alternating supply-demand imbalances and external trade pressures.聽
January opened with a noticeable price rise, as international buyers expedited procurement to hedge against expected U.S. tariff hikes. Supply chain congestion following the holiday season, elevated freight rates, and rising input costs further supported this upward price correction.聽
However, February saw a sharp reversal, with prices declining significantly amid persistent oversupply, subdued domestic demand, and widespread factory shutdowns during the Lunar New Year. Ongoing trade restrictions and high inventories across major importing regions like the U.S. and Germany compounded market weakness, pushing suppliers to adopt aggressive pricing and inventory reduction measures.
By March, the market regained footing as tighter supply conditions emerged. Strengthening demand from the pharmaceutical sector, proactive procurement amid growing trade tensions, and improved industrial sentiment鈥攔eflected by a PMI rise to 50.5鈥攈elped stabilize pricing. While CPI declines indicated easing inflation, manufacturers continued facing cost pressures from raw material constraints. The overall quarterly trend reflected a volatile landscape, transitioning from early optimism to mid-quarter weakness, and ending with marginal price recovery. Sustained demand, strategic procurement, and evolving trade dynamics are likely to dictate future pricing movements.
Europe
The European market for 10-Methoxy Iminostilbene, with Germany as a focal point, witnessed modest volatility in Q1 2025, shaped by strategic procurement, shifting demand patterns, and evolving macroeconomic indicators. January began with a marginal price increase of 0.4%, driven by proactive purchasing from pharmaceutical manufacturers preparing for potential Lunar New Year supply constraints in Asia. Stable output from Asian producers and consistent inquiries helped maintain a balanced supply-demand environment, with elevated import costs and maritime delays adding slight upward pressure.
In February, the market reversed course, posting a notable price decline due to weak downstream demand and improved supply chain performance. Higher inventory levels from pre-holiday stockpiling, reduced ocean freight rates, and a stronger euro contributed to pricing softness. Pharmaceutical and food sectors adopted a cautious stance, reflecting subdued consumer sentiment and election-related uncertainty.
The bearish trend extended into March, as oversupply persisted and import prices from China dropped. Weakened buyer sentiment, driven by trade policy disruptions and a softening euro, further restrained procurement activity. While lower freight costs supported affordability, they were insufficient to offset the impact of market saturation. Overall, Q1 2025 in Europe reflected a transition from early-quarter stability to continued pricing weakness amid muted demand and ample supply.
For the Quarter Ending December 2024
North America
The U.S. 10-Methoxy Iminostilbene market experienced a sharp decline in prices throughout Q4 2024, driven by weak demand and intense competition. During Q4 2024, the U.S. 10-Methoxy Iminostilbene market saw a consistent downward trajectory in prices. This decline was fueled by ample domestic inventories, reduced export prices, and sluggish demand from key sectors like pharmaceuticals. Aggressive pricing strategies by suppliers, especially as the holiday season neared, intensified the pressure on prices. Additionally, the market faced competition from lower-cost Chinese imports, exacerbating the oversupply situation.
Concerns over upcoming disruptions in January 2025, including potential port operation issues and proposed tariffs ranging from 10-60%, added to the cautious sentiment among buyers. Elevated inventories at major ports like Seattle and Los Angeles signaled logistical challenges, compelling businesses to rethink supply chain strategies.
While some downstream applications sustained stable demand, the export market remained subdued due to weak buyer activity and high inventories. Overall, the market reflected a pessimistic outlook for the quarter, with the ongoing destocking efforts by domestic suppliers dominating the landscape.聽
Asia Pacific
The 10-Methoxy Iminostilbene market in China demonstrated mixed trends, with an initial strong seller鈥檚 market transitioning to a buyer鈥檚 market by the end of the quarter. In early Q4 2024, the Chinese 10-Methoxy Iminostilbene market saw stable price increases due to robust global demand following the holiday season. Limited supply, heightened overseas inquiries, and a slowdown in feedstock shipments tightened supply chains, allowing manufacturers to raise prices and optimize profit margins.聽
Falling freight rates further supported international buyers, enabling bulk purchases despite higher prices. China's dominant position as the leading producer and exporter bolstered its influence, capitalizing on strong domestic and international demand. However, by late Q4, the market faced a reversal. High inventories, weak demand, and tariff threats from the incoming U.S. administration pressured suppliers to aggressively destock through discounts.聽
Currency manipulation exacerbated pricing instability, creating a challenging landscape for sellers. Buyers adopted a cautious approach, limiting purchases to immediate needs, which deepened the supply-demand imbalance. By the quarter's end, the market shifted to a buyer鈥檚 market, with price pressures expected to persist unless demand rebounds or production adjusts downward.聽
Europe
The German 10-Methoxy Iminostilbene market faced a consistent downward price trend throughout Q4 2024, driven by weak demand, surplus supply, and economic challenges in the eurozone. In October, prices began declining as favorable production conditions and excessive stock levels intensified competition.聽
By November, the downturn deepened, exacerbated by subdued demand, surplus inventory, and aggressive price-cutting strategies by suppliers. Limited industrial activity and cautious procurement behavior further dampened the market. The depreciation of the Euro against the dollar and muted business confidence reinforced bearish sentiment, as buyers adhered to a need-based approach.
In December, the decline persisted, with Germany鈥檚 Manufacturing PMI dropping to 42.5, signaling reduced industrial output and weaker new orders. Demand across multiple sectors remained sluggish, compelling manufacturers to adopt conservative inventory strategies. Pre-holiday stockpiling and stable downstream consumption failed to mitigate surplus supply, while limited export opportunities further pressured prices.
